Health TrialsbyHealthPanel

CLIMB: CNS Lymphoma Imaging and Molecular Biomarkers Study

ConditionCNS Lymphoma
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorRoyal Marsden NHS Foundation Trust

About this trial

A prospective imaging and translational tissue study in CNS lymphoma to enable further disease characterisation and the development of potential predictive and prognostic biomarkers.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Subjects capable of giving informed consent, or if appropriate, if subject's capacity is deemed limited due to CNS involvement, a consultee can provide consent on their behalf. Some patients with PCNSL may be incapable of providing their own consent due to the neurological effects of their disease. In these cases the patient will be classed as an incapacitated adult and a legal representative will be sought in accordance with English or Scottish law as applicable (see 7.2.1)

A radiological or histological diagnosis of primary CNS lymphoma.

Have not received prior CNS directed therapy. Prior use of steroids is permitted.

Participants aged ≥18 years old.

Disqualifiers

None

Trial population

Patients with newly diagnosed primary CNS lymphoma

Trial design

Design model

Case-only

Time perspective

Prospective

Treatments tested in this trial

Not listed

Trial groups

36 Participants
are grouped into 1 trial group
Group A: Patients with a new diagnosis of primary or secondary CNS lymphoma

Trial outcomes

Primary outcomes

1

Plasma ctDNA detection

To assess if plasma ctDNA detection measured from end of treatment (using the tumour informed approach) can be used an early detection tool for progressive disease.

Time frame
5 Years
2

Contrast clearance analysis

To assess the results of contrast clearance analysis

Time frame
5 Years

Secondary outcomes

1

Plasma ctDNA detection from end of treatment

To assess if plasma ctDNA detection measured from end of treatment (using the tumour agnostic approach) can be used as an early detection tool for progressive disease

Time frame
5 Years
2

Plasma ctDNA detection rate at baseline

To assess plasma ctDNA detection rate at baseline using the (i) tumour agnostic and (ii) tumour informed approach

Time frame
5 Years
3

Plasma ctDNA detection at end of treatment

To assess whether plasma ctDNA detection at end of treatment can be used an early detection tool for progressive disease and survival using the (i) tumour agnostic and (ii) tumour informed approach

Time frame
5 Years
4

Plasma ctDNA detection rate at disease progression

To assess plasma ctDNA detection rate at disease progression using the (i) tumour agnostic and (ii) tumour informed approach

Time frame
5 Years

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Royal Marsden NHS Foundation Trust

Lead sponsor

Source ClinicalTrials.gov
Apply now